Wire · opportunities
Sanofi's Infilbray wins first approval for neurological symptoms of Type 3 Gaucher disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 November 2026 · Fusion42 review
The US FDA approved Sanofi’s Infilbray (venglustat) as the first treatment for neurological symptoms of Type 3 Gaucher disease, based on Phase III trial results demonstrating superior motor and cognitive outcomes compared to imiglucerase. This is the first global approval of venglustat, with adult and pediatric indications and safety warnings included in the US label.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 18 Nov 2026 and 20 Nov 2026.
◆ ◆ The Wire takeaway
You now have a regulatory green light to develop therapies targeting neurological symptoms of Type 3 Gaucher disease in the US. This approval opens a new pathway for rare disease treatments crossing the blood-brain barrier to reach patients with unmet neurological needs.
◆ Coverage
7 sources · first reported 18 Nov 2026 · latest 20 Nov 2026
◆ Related on Wire
◆ Topics